Search clinical trials for: atrasentan hydrochloride

Total 7351 results

Daiichi Sankyo, Inc.

Completed

Effects on Colesevelam HC1 (WelChol®) on Insulin Sensitivity in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

United States
University of Chicago
National Cancer Institute (NCI)

Completed

Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma

Malignant Peritoneal Mesothelioma

United States
Taro Pharmaceuticals USA

Terminated

Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams as Compared to Lotrimin Ultra Cream in Patients With Interdigital Tinea Pedis (BNF-0909)

Interdigital Tinea Pedis
Mayo Clinic
National Comprehensive Cancer Network

Completed

Trifluridine/Tipiracil and Irinotecan for the Treatment of Advanced Refractory Biliary Tract Cancer

Stage III Gallbladder Cancer AJCC v8 | Stage IIIA Gallbladder Cancer AJCC v8 | Stage IIIB Gallbladder Cancer AJCC v8 | Refractory Gallbladder Carcinoma | Stage IV Gallbladder Cancer AJCC v8 | Stage IV Distal Bile Duct Cancer AJCC v8 | Stage IV Intrahepatic Bile Duct Cancer AJCC v8 | Stage IVB Gallbladder... and other conditions

United States
National Cancer Institute (NCI)

Completed

Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer

Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage II Pancreatic Cancer

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Adult Hodgkin Lymphoma | Recurrent Adult T-cell Leukemia/Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Withdrawn

Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma

United States
Zujiang YU

Not yet recruiting

Prevention of Cancer Development and Progression

Cancer
National Cancer Institute (NCI)

Active, not recruiting

Pazopanib Hydrochloride in Treating Patients With Advanced or Refractory Solid Tumors

Solid Neoplasm

United States
Amgen

Completed

A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States, Australia, Italy, United Kingdom, Germany, France
Brigham and Women's Hospital

Completed

Phase III Study of L-Cysteine in Patients With Erythropoietic Protoporphyria

Erythropoietic Protoporphyria
Laboratoires Thea

Active, not recruiting

Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.

Ocular Hypertension | Glaucoma

United States
Telik

Terminated

Study of Ezatiostat (Telintra Tablets) for Treatment of Severe Chronic Neutropenia

Severe Chronic Neutropenia

United States
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC

Lung Cancer

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients

Liver Dysfunction

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

Small Cell Lung Carcinoma

China
Sumitomo Pharma Co., Ltd.

Terminated

Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer (ED-SCLC)

Small-cell Lung Cancer

Japan
University Health Network, Toronto

Completed

Study of Intratumoral Hypoxia Using Pre-operative Administration of Pimonidazole

Pancreatic Cancer

Canada
National Cancer Institute (NCI)

Completed

Pazopanib in Treating Patients With Metastatic Urothelial Cancer

Recurrent Bladder Cancer | Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter | Stage IV Bladder Cancer | Transitional Cell Carcinoma of the Bladder | Distal Urethral Cancer | Proximal Urethral Cancer | Recurrent Urethral Cancer | Urethral Cancer Associated With Invasive Bladder Cancer

United States, China, Korea, Republic of
National Cancer Institute (NCI)

Completed

17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
BioCryst Pharmaceuticals

Completed

Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer

Ductal Breast Carcinoma in Situ | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Atypical Ductal Breast Hyperplasia | Lobular Breast Carcinoma in Situ

United States
Aziende Chimiche Riunite Angelini Francesco S.p.A
Zak-Pharma Dienstleistung Ges.m.b.H.

Completed

Benzydamine in Sore Throat Pain Relief (BePaiR Study) (BePaiR)

Acute Sore Throat

Hungary, Poland, Russian Federation
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)

Pancreatic Cancer

United States
University Health Network, Toronto
National Cancer Institute (NCI)

Completed

Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

Canada
Daiichi Sankyo, Inc.

Completed

WelChol® and Insulin in Treating Patients With Type 2 Diabetes

Type 2 Diabetes

United States, Peru, Mexico
Cephalon

Completed

Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin's Lymphoma (NHL)

United States, Belgium, Israel
Allerderm

Completed

Bioequivalence of Ethylenediamine Dihydrochloride Study

Allergic Contact Dermatitis

United States
Merck Sharp & Dohme LLC

Completed

Study of Changes in Hepatic Fat Following Administration of MK-4074 and Pioglitazone Hydrochloride (MK-4074-008)

Non-alcoholic Fatty Liver Disease
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Study of Desvenlafaxine in Treating Major Depressive Disorder.

Major Depressive Disorder

China
University of California, Davis
National Cancer Institute (NCI); Novartis Pharmaceuticals

Completed

INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer

Recurrent Non-small Cell Lung Cancer

United States
Menzies School of Health Research

Completed

Optimum Thiamine Intervention (OpTIn) Trial (OpTIn)

Wernicke-Korsakoff Syndrome

Australia
Merck Sharp & Dohme LLC

Completed

A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)

Carcinoma, Non-small-cell Lung
NCIC Clinical Trials Group
GlaxoSmithKline

Completed

MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy

Lung Cancer

Canada
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI); Astellas Pharma Inc; OSI Pharmaceuticals

Completed

Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

Pancreatic Cancer

United States, Canada
Northwestern University
Genentech, Inc.; Amgen; OSI Pharmaceuticals

Completed

Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer

Colorectal Cancer

United States
German CLL Study Group

Completed

Bendamustine and Mitoxantrone in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Germany
Centre Antoine Lacassagne

Completed

Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer

Pancreatic Cancer

France
National Cancer Institute (NCI)

Completed

S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Stage IV Pancreatic Cancer

United States
Xijing Hospital

Recruiting

Association Between Postoperative Administration of L-Arginine and CSA-AKI

Acute Kidney Injury

China
Shanghai Mental Health Center
Yantai University

Recruiting

Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)

Major Depressive Disorder

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis

Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi

China
Eiger BioPharmaceuticals

Completed

Safety and Tolerability Study of Clemizole Hydrochloride to Treat Hepatitis C in Subjects Who Are Treatment-Naive (CLEAN-1)

Hepatitis C
Millendo Therapeutics US, Inc.

Terminated

Nevanimibe HCl for the Treatment of Classic CAH

Congenital Adrenal Hyperplasia

Spain, Israel, France, Brazil, Czechia
Medstar Health Research Institute

Completed

The Effect of Reloading Prasugrel in a Patient Who Has Already Received a Loading Dose (LD) of Clopidogrel (SWITCH 600/60)

Acute Coronary Syndrome

United States
National Cancer Institute (NCI)

Completed

Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Thyroid Gland Anaplastic Carcinoma | Stage III Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7 | Stage IVC Differentiated Thyroid Gland Carcinoma... and other conditions

United States, Taiwan, Australia, Singapore, China
New Approaches to Brain Tumor Therapy Consortium
National Cancer Institute (NCI)

Completed

Procarbazine in Treating Patients With Recurrent Brain Tumor

Brain and Central Nervous System Tumors

United States
Toray Industries, Inc

Completed

Phase II Study of TRK-820 Soft Capsules - Intractable Pruritus in Patients With Chronic Liver Disease -

Pruritus With Chronic Liver Disease

Japan
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

A Clinical Trial to Evaluate TQB2858 Injection Combined With Anlotinib Hydrochloride Capsule in the Treatment of Recurrent or Metastatic Advanced Endometrial Carcinoma

Endometrial Carcinoma

China
National Cancer Institute (NCI)

Completed

Pazopanib in Treating Patients With Recurrent or Metastatic Breast Cancer

Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

Canada

Search clinical trials for: atrasentan hydrochloride

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saudi Arabia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations